Full Press Release Details
Ascentage Pharma To Present Data from Two Clinical
Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
ROCKVILLE, Md. and SUZHOU, China, April 23, 2025 (GLOBE NEWSWIRE) --
Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company engaged in discovering, developing, and commercializing
therapies to address global unmet medical needs primarily for hematological malignancies, today announced that results from two clinical
studies of the Bcl-2 selective inhibitor lisaftoclax (APG-2575) and the MDM2-p53 inhibitor alrizomadlin (APG-115), two key drug candidates
in the company's apoptosis-targeted pipeline, have been selected for presentations at the 2025 American Society of Clinical Oncology
(ASCO) Annual Meeting. These presentations will include an oral report featuring updated results from a Phase Ib/II study of a lisaftoclax
combination regimen in patients with myeloid malignancies.
The ASCO Annual Meeting showcases the most cutting-edge research in
clinical oncology and state-of-the-art advanced cancer therapies and is the world's most influential and prominent scientific gathering
of the clinical oncology community, bringing together more than 40,000 oncology professionals from across the globe. This year's
ASCO Annual Meeting will take place both online and in-person at McCormick Place, Chicago, IL, the United States, on May 30-June
Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma, said,
"We are honored to return to the ASCO Annual Meeting for the eighth consecutive year to present the latest data on our novel assets
and highlight the strength of our clinical development and global innovation. We look forward to sharing an oral presentation on a lisaftoclax
combination regimen in patients with treatment-na ve or prior venetoclax-exposed myeloid malignancies and a readout on alrizomadlin
in patients with advanced adenoid cystic carcinoma or other solid tumors. These presentations reflect our deep focus on advancing global
clinical development of our key assets in order to bring more treatment options to patients as soon as possible."
The clinical studies to be presented at this year's ASCO Annual
Meeting are as follows:
Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine
(AZA) in patients (pts) with treatment-na ve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies
A phase 2 study of novel MDM2 inhibitor
alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors.
About Ascentage Pharma
Ascentage Pharma is a global, integrated
biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily
in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the
stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol "AAPG"
The company has built a rich pipeline of innovative drug candidates
that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53; and next-generation TKIs that target
kinase mutants emergent during cancer treatment. Ascentage Pharma is also the only company in the world with active clinical programs
targeting all known key apoptosis regulators.
Olverembatinib, one of the company's lead assets, is approved
in China, with all of its approved indications included in the China National Reimbursement Drug List (NRDL). Meanwhile, a New Drug Application
(NDA) for another one of Ascentage Pharmas key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has been accepted
and granted a Priority Review designation by the China Center for Drug Evaluation.
To date, Ascentage Pharma has obtained a total of 16 Orphan Drug Designations
from the US FDA and 1 Orphan Designation from the European Medicines Agency of the European Union for 4 of the company's investigational
drug candidates. Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights
and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies such as
Takeda, Merck, AstraZeneca, Pfizer and Innovent; and research and development relationships with leading research institutions such as
Mayo Clinic, Dana-Farber Cancer Institute, National Cancer Institute (NCI) and the University of Michigan.
The company has built a talented team with a wealth of global experience
in the discovery and development of innovative drugs and fully functional commercial manufacturing and Sales & Marketing teams. One
pivotal aim of Ascentage Pharma is to continuously strengthen its R&D capabilities and accelerate its clinical development programs,
in order to fulfill its mission of addressing unmet clinical needs in China and around the world for the benefit of more patients.
Cautionary Note Regarding Forward-Looking
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act
of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All
statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements
that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future
events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and
uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled "Risk
factors" and "Special note regarding forward-looking statements and industry data" in its final prospectus for its
U.S. initial public offering, filed with the SEC on January 24, 2025 and the Form 20-F filed with the SEC on April 16, 2025, and other
filings with the SEC that the Company made or makes from time to time, and with respect to non-U.S. investors only, the sections headed
"Forward-looking Statements" and "Risk Factors" in the prospectus of the Company for its Hong Kong initial public
offering dated October 16, 2019, and other filings with The Stock Exchange of Hong Kong Limited it has made or it makes from time
to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute
profit forecast by the Company's management.
As a result of these factors, you should not rely on these forward-looking
statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's
current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements.
Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.
Hogan Wan, Head of IR and Strategy
Stephanie Carrington